<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-08T04:52:09Z</responseDate><request verb="GetRecord" identifier="oai:docta.ucm.es:20.500.14352/115839" metadataPrefix="oai_dc">https://docta.ucm.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:docta.ucm.es:20.500.14352/115839</identifier><datestamp>2025-01-24T00:48:01Z</datestamp><setSpec>com_20.500.14352_14</setSpec><setSpec>col_20.500.14352_15</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension</dc:title>
   <dc:creator>Martínez Martínez, Ernesto</dc:creator>
   <dc:creator>Calvier L,</dc:creator>
   <dc:creator>Fernández-Celis A,</dc:creator>
   <dc:creator>Rousseau E</dc:creator>
   <dc:creator>Jurado-López R</dc:creator>
   <dc:creator>Rossoni LV</dc:creator>
   <dc:creator>Jaisser F</dc:creator>
   <dc:creator>Zannad F</dc:creator>
   <dc:creator>Rossignol P,</dc:creator>
   <dc:creator>Cachofeiro Ramos, María Victoria</dc:creator>
   <dc:creator>López-Andrés N</dc:creator>
   <dc:subject>616.12-008.331.1</dc:subject>
   <dc:subject>aldosterona;</dc:subject>
   <dc:subject>fibrosis</dc:subject>
   <dc:subject>galectina 3</dc:subject>
   <dc:subject>hipertensión</dc:subject>
   <dc:subject>inflamación.</dc:subject>
   <dc:subject>Sistema cardiovascular</dc:subject>
   <dc:subject>24 Ciencias de la Vida</dc:subject>
   <dc:description>Hypertensive cardiac remodeling is accompanied by molecular inflammation and fibrosis, 2 mechanisms that finally affect cardiac function. At cardiac level, aldosterone promotes inflammation and fibrosis, although the precise mechanisms are still unclear. Galectin-3 (Gal-3), a β-galactoside-binding lectin, is associated with inflammation and fibrosis in the cardiovascular system. We herein investigated whether Gal-3 inhibition could block aldosterone-induced cardiac inflammation and fibrosis and its potential role in cardiac damage associated with hypertension. Aldosterone-salt-treated rats presented hypertension, cardiac inflammation, and fibrosis that were prevented by the pharmacological inhibition of Gal-3 with modified citrus pectin. Cardiac inflammation and fibrosis presented in spontaneously hypertensive rats were prevented by modified citrus pectin treatment, whereas Gal-3 blockade did not modify blood pressure levels. In the absence of blood pressure modifications, Gal-3 knockout mice were resistant to aldosterone-induced cardiac inflammation. In human cardiac fibroblasts, aldosterone increased Gal-3 expression via its mineralocorticoid receptor. Gal-3 and aldosterone enhanced proinflammatory and profibrotic markers, as well as metalloproteinase activities in human cardiac fibroblasts, effects that were not observed in Gal-3-silenced cells treated with aldosterone. In experimental hyperaldosteronism, the increase in Gal-3 expression was associated with cardiac inflammation and fibrosis, alterations that were prevented by Gal-3 blockade independently of blood pressure levels. These data suggest that Gal-3 could be a new molecular mechanism linking cardiac inflammation and fibrosis in situations with high-aldosterone levels, such as hypertension.</dc:description>
   <dc:description>Depto. de Fisiología</dc:description>
   <dc:description>Fac. de Medicina</dc:description>
   <dc:description>TRUE</dc:description>
   <dc:description>pub</dc:description>
   <dc:date>2025-01-23T12:37:56Z</dc:date>
   <dc:date>2025-01-23T12:37:56Z</dc:date>
   <dc:date>2015-10-01</dc:date>
   <dc:type>journal article</dc:type>
   <dc:type>VoR</dc:type>
   <dc:identifier>https://hdl.handle.net/20.500.14352/115839</dc:identifier>
   <dc:identifier>XXXX-XXXX</dc:identifier>
   <dc:identifier>10.1161/HYPERTENSIONAHA.115.05876</dc:identifier>
   <dc:identifier>0194-911X</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>Martínez-Martínez E, Calvier L, Fernández-Celis A, Rousseau E, Jurado-López R, Rossoni LV, Jaisser F, Zannad F, Rossignol P, Cachofeiro V, López-Andrés N. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension. 2015 Oct;66(4):767-75. doi: 10.1161/HYPERTENSIONAHA.115.05876. Epub 2015 Aug 3. PMID: 26238446.</dc:relation>
   <dc:rights>restricted access</dc:rights>
   <dc:format>application/pdf</dc:format>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>